Merck’s Cogentin recall
Executive Summary
Company recalling certain production lots of the supplemental Parkinson's Disease drug benztropin mesylate in 1 mg and 2 mg tablets because quality control testing showed that some tablet samples from previously released lots of medication may no longer meet the requirements for the specified amount of active ingredient. Merck says that it expects FDA to classify the recall of the supplemental Parkinson's disease medication as a Class III recall. The recall is the second for Merck this year. Earlier, the company recalled lots of the diuretic HydroDiuril.